EP1844006A2 - Taurine synthesis, production and utility as a medicine - Google Patents

Taurine synthesis, production and utility as a medicine

Info

Publication number
EP1844006A2
EP1844006A2 EP05818935A EP05818935A EP1844006A2 EP 1844006 A2 EP1844006 A2 EP 1844006A2 EP 05818935 A EP05818935 A EP 05818935A EP 05818935 A EP05818935 A EP 05818935A EP 1844006 A2 EP1844006 A2 EP 1844006A2
Authority
EP
European Patent Office
Prior art keywords
effective
concentrations
prevention
combinations
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05818935A
Other languages
German (de)
English (en)
French (fr)
Inventor
Magd Ahmed Kotb Abdalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magd Ahmed Kotb Abdalla
Original Assignee
Magd Ahmed Kotb Abdalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magd Ahmed Kotb Abdalla filed Critical Magd Ahmed Kotb Abdalla
Publication of EP1844006A2 publication Critical patent/EP1844006A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Definitions

  • bile salts the conjugate bases of bile acids.
  • the major bile salts are synthesized and secreted by as glycine or taurine conjugates.
  • Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulphonic acid) is a component of bile. It combines with cholic acid to form taurocholic acid. Cholic acid is the metabolic fate of cholesterol. The formation of cholic acid involves a pathway involving several hydroxylations and oxidation reactions. All water soluble vitamins participate in these reactions.
  • Taurine lowers cholesterol, and this action is potentiated by the presence of water soluble vitamins.
  • Taurine is effective in lowering hypercholesterolaemia, hypertriglyceridaemia and all lipid associated disorders as in cholestasis or nephrotic syndrome, etc.. also it is effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective. ( Taurine is also effective in gall stone dissolution.
  • Taurine is safe, and effective in normalizing high cholesterol, low density lipoproteins, or very low density lipoproteins.
  • Taurine is also essential for stabilizing brain cells against changes in blood osmolality, and in conversion of serotonin to endorphins. It is effective in depression, migraine, headache, Alzheimer disease, and in psychiatric and neurological diseases.
  • lipids, lipoproteins, cholesterol, and hypercholestrolaemia associated diseases, psychiatric and neurological diseases and in gall stone dissolution the following singly or combined are effective: a. Taurine b. Cysteine and/or acetyl cysteine, c. All water soluble vitamins.
  • the "a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders.
  • the “a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling cholestasis disorders of any aetiology. viii.
  • the "a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology.
  • the “a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention, dissolution and controlling gall stone diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05818935A 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine Withdrawn EP1844006A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
PCT/EG2005/000044 WO2006072259A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Publications (1)

Publication Number Publication Date
EP1844006A2 true EP1844006A2 (en) 2007-10-17

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05818935A Withdrawn EP1844006A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Country Status (15)

Country Link
EP (1) EP1844006A2 (pt)
JP (1) JP2008526789A (pt)
KR (1) KR20070091198A (pt)
CN (1) CN101146767A (pt)
AP (1) AP2007004084A0 (pt)
AU (1) AU2005324199A1 (pt)
BR (1) BRPI0519606A2 (pt)
CA (1) CA2593563A1 (pt)
EA (1) EA200701434A1 (pt)
IL (1) IL184221A0 (pt)
MA (1) MA29238B1 (pt)
MX (1) MX2007008196A (pt)
NO (1) NO20074937A (pt)
TN (1) TNSN07226A1 (pt)
WO (1) WO2006072259A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069500A1 (es) 2007-11-30 2010-01-27 Univ California Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina
CN103382170B (zh) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 一种牛磺酸的制备方法
CN106728405A (zh) * 2016-11-15 2017-05-31 陈思文 一种牛磺酸和水溶性茶多酚复方组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58140017A (ja) * 1981-12-22 1983-08-19 Junichi Azuma 心不全治療剤
JPH08208464A (ja) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd 高脂血症の治療及び予防薬
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
AU8003800A (en) * 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (zh) * 2000-06-30 2002-03-20 张永春 牛磺酸合锌的生产工艺
CN1268733C (zh) * 2004-07-20 2006-08-09 刘辉 牛磺酸功能啤酒及其生产工艺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006072259A3 *

Also Published As

Publication number Publication date
CN101146767A (zh) 2008-03-19
KR20070091198A (ko) 2007-09-07
WO2006072259A3 (en) 2007-10-04
WO2006072259A2 (en) 2006-07-13
IL184221A0 (en) 2008-12-29
AU2005324199A1 (en) 2006-07-13
MX2007008196A (es) 2008-02-22
AP2007004084A0 (en) 2007-08-31
TNSN07226A1 (en) 2008-11-21
MA29238B1 (fr) 2008-02-01
JP2008526789A (ja) 2008-07-24
CA2593563A1 (en) 2006-07-13
NO20074937A (no) 2007-09-28
BRPI0519606A2 (pt) 2009-02-25
EA200701434A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
CN113402405B (zh) 一种阳离子脂质、含该阳离子脂质的脂质体、含该脂质体的核酸药物组合物及其制剂和应用
TW589186B (en) Ascorbyl-phosphoryl-cholesterol
TW201726600A (zh) 陽離子性脂質
JPH09503222A (ja) サイトカイン産生阻害剤としてのヒドロキサム酸誘導体
EP0951909B1 (en) Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof
ITRM930399A1 (it) Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
JPH05148200A (ja) 筋障害および神経退行変性の処置のためのアシル−ｌ−カルニチン誘導体
EP1844006A2 (en) Taurine synthesis, production and utility as a medicine
JP5671483B2 (ja) 色素沈着予防又は改善剤
JP2002533421A (ja) Ｎａａｌａｄアーゼ阻害因子を用いる疾患処置法
FR2894968A1 (fr) Nouveaux derives de l&#39;oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
CA3202047A1 (en) Fucosyltransferase specific inhibition using fucose mimetics
JP7073384B2 (ja) 化合物及び使用方法
CN1466453A (zh) 用于治疗增生性皮肤病的脂肪酸类似物
US6451761B1 (en) N′N′-dichlorinated omega-amino acids and uses thereof
JP4226324B2 (ja) カルボン酸型脂質
FR2989087A1 (fr) Nouveaux composes oligosaccharides et leur utilisation cosmetique
WO2011030727A1 (ja) パンテチンリン酸エステルを含む外用剤
JP2001097867A (ja) 皮脂産生抑制剤
EP1234816B1 (de) Scyphostatin-Analoga als SMase-Inhibitoren
SK13932002A3 (sk) Farmaceutické kompozície, ktoré obsahujú oligosacharidy, oligosacharidy a ich príprava a použitie
WO2013068964A1 (en) Pharmaceutical composition for the prevention and the treatment of degenerative skin disorders especially caused by ionizing radiations
WO2024149331A1 (zh) 一种氨基脂质化合物、其制备方法和应用
WO2024183821A1 (zh) 可离子化脂质分子及其制备方法和应用
EP1655281B1 (fr) Sels de N-acyl-L-aspartate-b-mono-ester et/ou de N-acyl-L-glutamate-g-mono-ester, leur procédé de préparation et leur utilisation dans des compositions thérapeutique ou cosmétique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070731

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20071004

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103070

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105119

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20080128BHEP

Ipc: A61K 31/145 20060101ALI20080128BHEP

Ipc: C07C 303/02 20060101AFI20060720BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1103070

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105119

Country of ref document: HK